The theory was that biotechs would become the innovation engine of Big Pharma, creating the products that drug companies would commercialize. Now, the trend has reversed itself. Drug companies are helping biotechs fill their pipelines, but with this twist--biotechs are then going out and selling those products to someone else at higher valuations.
You may also be interested in...
The Canadian authorities have put in place an expedited pathway for authorizing new COVID-19 drugs and vaccines that offers a more agile approach to reviewing data than what was previously allowed.
The UK medicines regulator has a “unique opportunity” to evaluate the systems it operates and to “do things differently", according to its long-term interim head, June Raine.
No device-related warning letters were released by the US FDA the week of 22 September.